drugset / Trial / NCT00035126

EPO906 Therapy in Patients With Advanced Breast Cancer

NCT00035126

Phase 2 Completed 46 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause breast cancer.

Timeline

Start
2002-01
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule Intravenous

Indications